TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE D-

NCT07263594: A Study of DB-1324 in Advanced/Metastatic Gastrointestinal Tumors

Sponsor: DualityBio Inc. · Phase: PHASE1/PHASE2 · Area: ONCOLOGY · Target Enrollment: 127 pts

Competing Trials Overlap

7 Active Trials

Excess Burn Exposure

$6,165,390

Rescue Site Savings

+$4,084,080

Unlock Full NCT07263594 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07263594 Rescue Dossier →